Skip header and navigation

1 records – page 1 of 1.

Ustekinumab (Stelara) therapy

https://libcat.nshealth.ca/en/permalink/chpams35722
Nova Scotia Health Authority. Nova Scotia Collaborative IBD Program. Halifax, NS: Nova Scotia Health Authority , 2022.
Pamphlet Number
1695
Available Online
View Pamphlet
Your IBD health care provider believes treatment with a medication called ustekinumab may help to manage your inflammatory bowel disease (IBD). The brand name for ustekinumab is Stelara®. This pamphlet will give you basic information about ustekinumab to help you make an informed decision about whether or not to use this treatment. Topics include what ustekinumab is, how it works, how it is given, how long you will need to take it, and how much it will cost. Considerations before you start taki…
Available Online
View Pamphlet
Corporate Author
Nova Scotia Health Authority. Nova Scotia Collaborative IBD Program
Place of Publication
Halifax, NS
Publisher
Nova Scotia Health Authority
Date of Publication
2022
Format
Pamphlet
Language
English
Physical Description
1 electronic document (10 p.) : digital, PDF file
Subjects (MeSH)
Ustekinumab
Inflammatory Bowel Diseases - drug therapy
Subjects (LCSH)
Inflammatory bowel diseases
Crohn's disease
Ulcerative colitis
Specialty
Medications
Abstract
Your IBD health care provider believes treatment with a medication called ustekinumab may help to manage your inflammatory bowel disease (IBD). The brand name for ustekinumab is Stelara®. This pamphlet will give you basic information about ustekinumab to help you make an informed decision about whether or not to use this treatment. Topics include what ustekinumab is, how it works, how it is given, how long you will need to take it, and how much it will cost. Considerations before you start taking ustekinumab and while you are taking it are listed. Possible side effects, information about pregnancy and breast/chest feeding, and other important things to know are included.
Notes
Previous title: Ustekinumab (Stelara) therapy for Crohn's disease
Responsibility
Prepared by: Nova Scotia Collaborative IBD Program
Pamphlet Number
1695
Less detail